Acadia Pharmaceuticals
ACAD
215 hedge funds and large institutions have $3.47B invested in Acadia Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 78 increasing their positions, 68 reducing their positions, and 9 closing their positions.
322% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 9
15% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 68
14% more funds holding
Funds holding: 188 → 215 (+27)
6% more capital invested
Capital invested by funds: $3.26B → $3.47B (+$211M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
23% less call options, than puts
Call options by funds: $43.4M | Put options by funds: $56.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$52.1M |
| 2 |
PC
PointState Capital
New York
|
+$15.9M |
| 3 |
State Street
Boston,
Massachusetts
|
+$13.4M |
| 4 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$12.2M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$8.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$60.2M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$19.2M |
| 3 |
Jennison Associates
New York
|
-$17.8M |
| 4 |
FAM
Fred Alger Management
New York
|
-$17.3M |
| 5 |
Capital World Investors
Los Angeles,
California
|
-$13.3M |
ACAD Hedge Fund Activity: Q4 2015 in Review
215 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q4 2015, worth a combined $3.47B — up 6.5% from $3.26B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new ACAD positions and 9 closed out — a net gain of 29 holders — while 78 added to existing stakes and 68 trimmed.
The largest buyer was Westfield Capital Management, opening a new position worth an estimated $52.1M. The largest seller was Point72 Asset Management, cutting an estimated $60.2M.
- 215 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q4 2015, up from 188 in Q3 2015.
- Funds reported $3.47B of Acadia Pharmaceuticals stock for Q4 2015, up 6.5% quarter-over-quarter.
- 38 funds opened new Acadia Pharmaceuticals positions in Q4 2015 and 9 closed out, a net change of +29 holders.
- The largest Acadia Pharmaceuticals buyer in Q4 2015 was Westfield Capital Management, an estimated $52.1M added.
- The largest Acadia Pharmaceuticals seller in Q4 2015 was Point72 Asset Management, an estimated $60.2M sold.
Based on aggregated 13F filings for Q4 2015.